Skip to main content
Erschienen in: Neurological Sciences 2/2020

04.10.2019 | Original Article

Importance of intensive and prolonged rehabilitative treatment on the Guillain-Barrè syndrome long-term outcome: a retrospective study

verfasst von: Valeria Prada, Federico Massa, Alexander Salerno, Davide Fregosi, Alessandro Beronio, Carlo Serrati, Antonio Mannironi, Giovanni Mancardi, Angelo Schenone, Luana Benedetti

Erschienen in: Neurological Sciences | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Guillain-Barrè syndrome (GBS) is often associated with a residual disability. Nonetheless, poor and incomplete studies have been published addressed towards the assessment of importance of physiotherapy (FKT) in the recovery. The aim of the study was to explore the effects of prolonged FKT associated with medical therapy and to evaluate the long-term outcome.

Methods

A retrospective analysis was carried out on patients with GBS who needed to continue rehabilitation after hospitalization and admitted to the Neurological Department of La Spezia from 2003 to 2017. MRC and GBS-Disability scale (GBS-DS) were performed at the time of greatest clinical disability, after medical therapy, and at the end of the overall FKT. The final outcome evaluation was based on the ability to walk with or without support. ANOVA with Bonferroni post-test were used to compare MRC and GBS-DS.

Results

Ninety-six patients were admitted, but only 51 satisfied inclusion criteria. Forty patients performed intensive treatment for an average of 60.95 days, and 31 of them, once discharged, are required to continue FKT as outpatients for a mean period of 96.45 days. The mean value of MRC and GBS-DS post-FKT improved significantly compared with the post-medical therapy. Concerning walking, among the 40 patients who did not walk before therapy, 8 need support after the medical therapy and 4 (11.76%) cannot walk independently at the last follow-up.

Conclusions

In conclusion, FKT associated to medical therapy can improve the outcome of the disease, if performed for periods exceeding 6 months.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Sejvar JJ, Kohl KS, Gidudu J, Amato A, Bakshi N, Baxter R, Burwen DR, Cornblath DR, Cleerbout J, Edwards KM, Heininger U, Hughes R, Khuri-Bulos N, Korinthenberg R, Law BJ, Munro U, Maltezou HC, Nell P, Oleske J, Sparks R, Velentgas P, Vermeer P, Wiznitzer M, Brighton Collaboration GBS Working Group (2011) Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 29:599–612. https://doi.org/10.1016/j.vaccine.2010.06.003 CrossRefPubMed Sejvar JJ, Kohl KS, Gidudu J, Amato A, Bakshi N, Baxter R, Burwen DR, Cornblath DR, Cleerbout J, Edwards KM, Heininger U, Hughes R, Khuri-Bulos N, Korinthenberg R, Law BJ, Munro U, Maltezou HC, Nell P, Oleske J, Sparks R, Velentgas P, Vermeer P, Wiznitzer M, Brighton Collaboration GBS Working Group (2011) Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 29:599–612. https://​doi.​org/​10.​1016/​j.​vaccine.​2010.​06.​003 CrossRefPubMed
8.
Zurück zum Zitat McGrogan A, Madle GC, Seaman HE, De Vries CS (2009) The epidemiology of Guillain-Barré syndrome worldwide: a systematic literature review. Neuroepidemiology 32:150–163CrossRefPubMed McGrogan A, Madle GC, Seaman HE, De Vries CS (2009) The epidemiology of Guillain-Barré syndrome worldwide: a systematic literature review. Neuroepidemiology 32:150–163CrossRefPubMed
9.
Zurück zum Zitat Van Den Berg B, Walgaard C, Drenthen J et al (2014) Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol 10:469–482CrossRefPubMed Van Den Berg B, Walgaard C, Drenthen J et al (2014) Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol 10:469–482CrossRefPubMed
15.
Zurück zum Zitat Bernsen RA, Jacobs HM, de Jager AE, van der Meche FG (1997) Residual health status after Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 62:637–640CrossRefPubMedPubMedCentral Bernsen RA, Jacobs HM, de Jager AE, van der Meche FG (1997) Residual health status after Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 62:637–640CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Merkies ISJ, Schmitz PIM, Samijn JPA, van der Meche FGA, van Doorn PA (1999) Fatigue in immune-mediated polyneuropathies. Neurology 53:1648–1654CrossRefPubMed Merkies ISJ, Schmitz PIM, Samijn JPA, van der Meche FGA, van Doorn PA (1999) Fatigue in immune-mediated polyneuropathies. Neurology 53:1648–1654CrossRefPubMed
19.
Zurück zum Zitat Merkies IS, Schmitz PI, Samijn JP et al (1999) Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) group. Neurology 53:1648–1654CrossRefPubMed Merkies IS, Schmitz PI, Samijn JP et al (1999) Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) group. Neurology 53:1648–1654CrossRefPubMed
23.
Zurück zum Zitat Khan F, Amatya B (2012) Rehabilitation interventions in patients with acute demyelinating inflammatory polyneuropathy: a systematic review. Eur J Phys Rehabil Med 48:507–522PubMed Khan F, Amatya B (2012) Rehabilitation interventions in patients with acute demyelinating inflammatory polyneuropathy: a systematic review. Eur J Phys Rehabil Med 48:507–522PubMed
28.
Zurück zum Zitat Hadden RDM, Cornblath DR, Hughes RAC, Zielasek J, Hartung HP, Toyka KV, Swan AV, The Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group (1998) Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Ann Neurol 44:780–788. https://doi.org/10.1002/ana.410440512 CrossRefPubMed Hadden RDM, Cornblath DR, Hughes RAC, Zielasek J, Hartung HP, Toyka KV, Swan AV, The Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group (1998) Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Ann Neurol 44:780–788. https://​doi.​org/​10.​1002/​ana.​410440512 CrossRefPubMed
29.
Zurück zum Zitat Khan F, Pallant JF, Amatya B, Ng L, Gorelik A, Brand C (2011) Outcomes of high- and low-intensity rehabilitation programme for persons in chronic phase after Guillain-Barre syndrome: a randomized controlled trial. J Rehabil Med 43:638–646CrossRefPubMed Khan F, Pallant JF, Amatya B, Ng L, Gorelik A, Brand C (2011) Outcomes of high- and low-intensity rehabilitation programme for persons in chronic phase after Guillain-Barre syndrome: a randomized controlled trial. J Rehabil Med 43:638–646CrossRefPubMed
31.
Zurück zum Zitat Chiò a CD, Leone M et al (2003) Guillain-Barré syndrome: a prospective, population-based incidence and outcome survey. Neurology 60:1146–1150CrossRefPubMed Chiò a CD, Leone M et al (2003) Guillain-Barré syndrome: a prospective, population-based incidence and outcome survey. Neurology 60:1146–1150CrossRefPubMed
Metadaten
Titel
Importance of intensive and prolonged rehabilitative treatment on the Guillain-Barrè syndrome long-term outcome: a retrospective study
verfasst von
Valeria Prada
Federico Massa
Alexander Salerno
Davide Fregosi
Alessandro Beronio
Carlo Serrati
Antonio Mannironi
Giovanni Mancardi
Angelo Schenone
Luana Benedetti
Publikationsdatum
04.10.2019
Verlag
Springer International Publishing
Erschienen in
Neurological Sciences / Ausgabe 2/2020
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-019-04077-x

Weitere Artikel der Ausgabe 2/2020

Neurological Sciences 2/2020 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.